Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form
or email me firstname.lastname@example.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
2012-15: USA Trillionaires Attempting to Match VesCell 2004-06
Baxter Begins Phase III Adult Stem Cell Trial For Chronic Cardiac Condition
(RTTNews.com) - Baxter International Inc. (BAX), valued at over THREE TRILLION DOLLARS, said it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia. Should it succeed, and one actuary has placed the odds at very close to 100%, they will have proven what VesCell proved in 2004-06 with capital of less than ONE ONE-MILLIONTH of Baxter's current value!
Chronic myocardial ischemia is one of the most severe forms of coronary artery disease, causing significant long-term damage to the heart muscle and disability to the patient. VesCell (2005-2010) also treated over 200 non-ischemic patients with the same blood-derived stem cells.
Baxter said that the trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three arms, namely treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care. The primary objective is to evaluate the efficacy of treatment with CD34+ stem cells to improve the functional capacity of patients with chronic myocardial ischemia, as measured by a change in total exercise capacity at 12 months following treatment.
Efficacy will be measured by a change in total exercise capacity during the first year following treatment and safety data will be collected for two years. Exercise capacity (6 minute walk) was the key efficacy factor in the VesCell trial. Even better, that trial proved 100% safe, and none of the 500 no-hope heart patients treated after that trial was harmed by the patient's own blood-derived stem cells---still in use today and still no one can top them with published scientific data....no one.
Baxter noted that the trial is being initiated based on the phase II data, which indicated that injections of patients' own CD34+ stem cells may improve exercise capacity and reduce reports of angina episodes in patients with chronic, severe refractory angina.
Finally, I have long claimed that no serious heart stem cell treatment which can affect Big Medicine's profits will be approved in any developed country by 2020. Nothing here has changed that.
Don Margolis, Chairman
Repair Stem Cell Institute